Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med LLC
Orano Med LLC
Degron Therapeutics Co.
National Cancer Institute (NCI)
Prelude Therapeutics
ABM Therapeutics Corporation
Sumitomo Pharma America, Inc.
Quadriga Biosciences, Inc.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Celgene
Tocagen Inc.
Roswell Park Cancer Institute
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Pharmacyclics LLC.